Biolegend, 302012, APC anti-human CD16 Antibody, 100tests

CD16 is known as low affinity IgG receptor III (FcγRIII). It is expressed as two distinct forms (CD16a and CD16b). CD16a (FcγRIIIA) is a 50-65 kD polypeptide-anchored transmembrane protein. It is expressed on the surface of NK cells, activated monocytes, macrophages, and placental trophoblasts in humans. CD16b (FcγRIIIB) is a 48 kD glycosylphosphatidylinositol (GPI)-anchored protein. Its extracellular domain is over 95% homologous to that of CD16a, and it is expressed specifically on neutrophils. CD16 binds aggregated IgG or IgG-antigen complex which functions in NK cell activation, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC).
100tests
Verified Reactivity: Human, Cynomolgus, Rhesus
Reported Reactivity: African Green, Baboon, Capuchin Monkey, Chimpanzee, Common Marmoset, Pigtailed Macaque, Sooty Mangabey, Squirrel Monkey
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: Human PMN cells
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation: The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The CD16 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
Excitation Laser: Red Laser (633 nm)
Application Notes: The 3G8 antibody clone blocks neutrophil phagocytosis and stimulates NK cell proliferation. It has been reported that this clone interacts with the FcγRIIa and FcγRIIIb receptors causing neutrophil activation and aggregation18. Due to this phenomenon staining in whole blood may cause a reduction in the number of granulocytes or alter their scatter profile.Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections6, immunoprecipitation3, stimulation of NK cell proliferation4, blocking of phagocytosis5, and blocking of immunoglobulin binding to FcγRIII7,8. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 302049, 302050, 302057, 302058).
Application References(PubMed link indicates BioLegend citation): Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York. Edberg J, et al. 1997. J. Immunol. 159:3849. (IP) Hoshino S, et al. 1991. Blood 78:3232. (Stim) Tamm A, et al. 1996. Immunol. 157:1576. (Block) Da Silva DM, et al. 2001. Int. Immunol. 13:633. (IHC) Holl V, et al. 2004. J. Immunol. 173:6274. (Block) Hober D, et al. 2002. J. Gen. Virol. 83:2169. (Block) Brainard DM, et al. 2009. J. Virol. 83:7305. PubMed Smed-Sörensen A, et al. 2008. Blood 111:5037. (Block) PubMed Timmerman KL, et al. 2008. J. Leukoc. Biol. 84:1271. (FC) PubMed Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC) Rout N, et al. 2010. PLoS One 5:e9787. (FC) Kim WK, et al. 2006. Am. J. Pathol. 168:822. (FC) Boltz A, et al. 2011. J. Biol Chem. 286:21896. PubMed Wu Z, et al. 2013. J. Virol. 87:7717. PubMed Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG) Vossebeld PJ, et al. 1997. Biochem J. 323:87-94 (Stim)
Product Citations: Guo Y, et al. 2021. Exp Ther Med. 353:21. PubMed Rizzo MD, et al. 2019. J Pharmacol Exp Ther. 371:191. PubMed Jowett GM, et al. 2022. Cell Rep. 40:111281. PubMed Wu X, et al. 2023. iScience. 26:106559. PubMed Li J, et al. 2023. Sci Rep. 13:7501. PubMed Ait Djebbara S, et al. 2023. Front Immunol. 14:1180900. PubMed Li Y, et al. 2022. J Med Virol. 94:3998. PubMed Shemesh A, et al. 2022. J Exp Med. 219: . PubMed Dolislager CG, et al. 2022. J Leukoc Biol. 112:1457. PubMed Ali LR, et al. 2023. J Exp Med. 220: . PubMed Gopinath A, et al. 2020. J Immunol Methods. 476:112686. PubMed Meya D, et al. 2015. J Infect Dis. 211:1597. PubMed Cruz MA, et al. 2022. Nat Nanotechnol. 17:1004. PubMed Pazina T, et al. 2019. Cancer Immunol Res. 7:1633. PubMed Hagan T, et al. 2020. Cell. 178(6):1313-1328.e13.. PubMed Guney-Esken G, et al. 2021. Stem Cell Res Ther. 12:287. PubMed Wang H, et al. 2022. Front Immunol. 13:852436. PubMed Wang H, et al. 2020. Onco Targets Ther. 13:3903. PubMed Rademacher MJ, et al. 2021. Sci Rep. 11:8321. PubMed Hünniger K, et al. 2015. J Immunol. 194:1199. PubMed Grenga I, et al. 2016. Clin Transl Immunology. 0.265972222. PubMed Tang-Huau TL, et al. 2018. Nat Commun. 9:2570. PubMed Zhong J, et al. 2018. Sci Adv. 4:eaas9864. PubMed Guo L, et al. 2019. Breast Cancer Res Treat. 175:459. PubMed Kho D, et al. 2017. PLoS One. 10.1371/journal.pone.0180267. PubMed Paris O, et al. 2022. Front Immunol. 13:975910. PubMed Beatson RE, et al. 2021. Cell Rep Med. 2:100473. PubMed Xia Y, et al. 2019. Gastroenterol Res Pract. 2019:5436961. PubMed González-Tajuelo R, et al. 2020. Front Immunol. 11:588212. PubMed EC O, et al. 2015. Sci Rep. 5: 11888. PubMed Ge S, et al. 2012. Nephrol Dial Transplant. 209:35:00. PubMed Grivas A, et al. 2022. Front Immunol. 13:964274. PubMed Saha R, et al. 2021. Sci Rep. 11:18849. PubMed Gopinath A, et al. 2022. NPJ Parkinsons Dis. 8:72. PubMed Chen J, et al. 2017. J Immunol. 10.4049/jimmunol.1700159. PubMed Kim MY, et al. 2018. Cell. 173:1439. PubMed Rizzo MD, et al. 2018. AIDS. 32:419. PubMed Rydbirk R, et al. 2019. Sci Rep. 9:7781. PubMed Motwani MP, et al. 2018. JCI Insight. 3:e94463. PubMed Wang H, et al. 2011. Immunol Lett. 136:21. PubMed Rizzo MD, et al. 2019. J Neuroimmunol. 333:576969. PubMed Ruth JH, et al. 2021. JCI Insight. 6:e145662. PubMed Hiatt J, et al. 2021. Cell Reports. 35(6):109105. PubMed Yabe IM, et al. 2018. Mol Ther Methods Clin Dev. 11:143. PubMed Hilt ZT, et al. 2019. JCI Insight. 4:5. PubMed Zhai Y, et al. 2018. Autophagy. 1.714583333. PubMed Li M, et al. 2020. Virol Sin. 35:588. PubMed Tamminga M, et al. 2020. Transl Lung Cancer Res. 1.134027778. PubMed
RRID: AB_314211 (BioLegend Cat. No. 302011) AB_314212 (BioLegend Cat. No. 302012)
Structure: Ig superfamily, transmembrane form (50-65 kD) or GPI-linked form (48 kD)
Distribution: NK cells, activated monocytes, macrophages, neutrophils
Function: Low affinity IgG Fc receptor, phagocytosis, ADCC
Ligand/Receptor: Aggregated IgG, IgG-antigen complex
Cell Type: Dendritic cells, Macrophages, Monocytes, Neutrophils, NK cells
Biology Area: Immunology, Innate Immunity
Molecular Family: CD Molecules, Fc Receptors
Antigen References: 1. Fleit H, et al. 1982. P. Natl. Acad. Sci. USA 79:3275. 2. Stroncek D, et al. 1991. Blood 77:1572. 3. Wirthmueller U, et al. 1992. J. Exp. Med. 175:1381.
Gene ID: 2214
UniProt: View information about CD16 on UniProt.org
Clone: 3G8
Regulatory Status: RUO
Workshop: V NK80
Other Names: FcγRIII, Fc gamma receptor, Fc gamma receptor 3
Isotype: Mouse IgG1, κ
Q: Is our human Trustain FcX™ (cat# 422302) compatible with anti human CD16, CD32 and CD64 clones 3G8, FUN-2 and 10.1 respectively?
A: Yes